# Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients

> **NCT04940546** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 36 (actual)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04940546
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-16
- **Primary completion:** 2023-10-30
- **Final completion:** 2025-10-30
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04940546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04940546, "Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04940546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*